Antwerp

• A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet … Ended
  2024-512220-11-00 3 2024-05-23 Inflammatory Conditions
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to … Ended
  2023-504564-42-00 4 2024-04-08 Moderate to Severe Rheumatoid Arthritis
• A study to assess the effect of single and repeated doses of JNJ-81241459 on a single dose of certain other drugs, when given together to he … Ended
  2023-509030-19-00 3 2024-03-18 Plaque Psoriasis
• A pilot single center, open label trial to assess the impact of doxycycline postexposure prophylaxis on antimicrobial resistance (SafeDoxyPE … Ended
  2023-507137-24-00 4 2024-03-13 Bacterial sexually transmittable diseases (chlamydia, gonorrhea, syphi
• A single blind, placebo controlled, single center, randomized controlled pilot study to assess if low dose ciprofloxacin can induce antimicr … Ended
  2023-506205-18-00 4 2024-02-23 antimicrobial resistance in Escherichia coli
• SAFE study: Stopping Antibiotics after 3 days for the treatment of FEbrile Neutropenia in Haematology patients, a randomized open-label non- … Ended
  2022-500389-84-00 6 2024-02-16 Febrile neutropenia
• A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered to … Ended
  2023-506580-34-00 3 2024-01-04 Healthy Volunteers
• A study on the reactogenicity, safety, immune response, and efficacy of a targeted immunotherapy against HSV in healthy participants aged 18 … Ended
  2024-510571-37-00 7 2023-12-06 Herpes Simplex
• Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy (EXPA … Ended
  2023-503830-27-00 4 2023-10-17 Large B-Cell Lymphoma (LBCL)
• A study to investigate JNJ-80202135 (nipocalimab) delivered subcutaneously via prefilled syringe autoinjector and via normal syringe Ended
  2023-504280-16-00 3 2023-10-17 Healthy Volunteers
• A Study to Evaluate the Safety and Tolerability of JNJ-77730614 When Given as Single and Multiple Doses to Healthy Participants to Assess Ho … Ended
  2023-505684-36-00 1 2023-10-09 Healthy Volunteers
• A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refr … Ended
  2022-502057-33-00 7 2023-10-02 Relapsed/refractory multiple myeloma
• A clinical trial to evaluate the absolute bioavailability and metabolic profile of aticaprant when administered as an oral tablet and a micr … Ended
  2022-502969-19-00 3 2023-09-27 Healthy Adult Participants
• A Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety, and reactogenicity of respirat … Ended
  2022-501988-40-00 5 2023-08-17 RSV-associated (subtypes A and B) disease in adults aged 60 years of a
• Clinical trial of MK-7648A in adults and children with skin cancer Ended
  2022-501417-31-01 5 2023-08-01 melanoma
• A study investigating the absorption and food effect of different tablet formulations of JNJ-77242113, a new compound in the treatment of in … Ended
  2023-504720-26-00 3 2023-07-19 Inflammatory Conditions
• A trial to learn how well REGN9933 works for preventing blood clots after knee replacement surgery in adult participants Ended
  2022-501470-18-00 4 2023-06-26 Thromboembolic disease
• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Ended
  2022-500536-11-01 5 2023-06-08 Moderately to severely active ulcerative colitis
• A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended
  2022-500101-41-00 6 2023-06-07 Type 2 Diabetes
• A study to evaluate the effect of multiple doses of carbamazepine on how long aticaprant (JNJ-67953964) stays in the body (pharmacokinetics) … Ended
  2022-502951-77-00 3 2023-05-05 Healthy Adult Participants
• A study to find and confirm the dose and assess the safety, reactogenicity and immune response of a vaccine against influenza in healthy you … Ended
  2022-502308-66-00 7 2023-04-27 Healthy volunteers (prevention of influenza infection)
• OMX-0407 Phase I Study Ended
  2024-514554-75-00 1 2023-03-16 Previously treated unresectable solid tumours
• C4951004 - BHV3000-406: A Phase 4, Randomized, Double-blind Placebo Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute … Ended
  2024-513269-37-00 6 2023-03-14 Migraine attacks with or without aura
• C4951012 - BHV3000-407: A Phase 4, Randomized, Double-blind, Placebo controlled Study to Evaluate the Efficacy and Tolerability of Rimegepan … Ended
  2024-513270-21-00 6 2023-03-14 migraine headaches with or without aura

Showing 193–216 of 249 trials